PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 174 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2017. The put-call ratio across all filers is 0.97 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $360,000 | -20.4% | 6,090 | -8.4% | 0.00% | -33.3% |
| Q1 2018 | $452,000 | -54.8% | 6,646 | -34.4% | 0.00% | -57.1% |
| Q4 2017 | $1,001,000 | +241.6% | 10,129 | +314.1% | 0.01% | +250.0% |
| Q3 2017 | $293,000 | +38.9% | 2,446 | +1.3% | 0.00% | +100.0% |
| Q2 2017 | $211,000 | +3.9% | 2,414 | -20.4% | 0.00% | 0.0% |
| Q3 2016 | $203,000 | +76.5% | 3,031 | -21.2% | 0.00% | 0.0% |
| Q2 2016 | $115,000 | +16.2% | 3,848 | +13.7% | 0.00% | 0.0% |
| Q1 2016 | $99,000 | -49.7% | 3,383 | +34.4% | 0.00% | 0.0% |
| Q4 2015 | $197,000 | +68.4% | 2,518 | +62.5% | 0.00% | 0.0% |
| Q3 2015 | $117,000 | -10.7% | 1,550 | +37.7% | 0.00% | 0.0% |
| Q2 2015 | $131,000 | -32.5% | 1,126 | +37.0% | 0.00% | -50.0% |
| Q1 2015 | $194,000 | +25.2% | 822 | +0.1% | 0.00% | +100.0% |
| Q4 2014 | $155,000 | -29.2% | 821 | -10.7% | 0.00% | -50.0% |
| Q3 2014 | $219,000 | +236.9% | 919 | -6.4% | 0.00% | +100.0% |
| Q2 2014 | $65,000 | – | 982 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 200,000 | $20,706,000 | 6.01% |
| Redmile Group, LLC | 230,673 | $23,882,000 | 2.95% |
| WEATHERBIE CAPITAL, LLC | 241,419 | $24,994,000 | 2.31% |
| Tekla Capital Management LLC | 185,820 | $19,238,000 | 2.02% |
| Ghost Tree Capital, LLC | 25,000 | $2,588,000 | 1.59% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $588,741,000 | 1.56% |
| Iguana Healthcare Management, LLC | 25,000 | $2,588,000 | 1.48% |
| Eventide Asset Management | 42,100 | $4,359,000 | 1.34% |
| Bain Capital Public Equity Management, LLC | 401,330 | $41,550,000 | 1.17% |
| Rock Springs Capital Management LP | 31,500 | $3,261,000 | 1.16% |